Indicator measures ER/PR and HER2 testing among women with invasive breast cancer

Current Oncology

Volumn 20, Issue 1, 2013, Pages 62-63

  Sandoval, C ^a   Rahal, R ^a   Forte, Tonia ^a   Klein Geltink, J ^a   He, D ^a   Bryan, H ^a,b  

^a NB   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANADA; CANCER CONTROL; CANCER DIAGNOSIS; CANCER INVASION; CANCER STAGING; HUMAN; IMMUNOHISTOCHEMISTRY;

EID: 84873432809     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.20.1290     Document Type: Article

References (3)

1. Allred DC, Carlson RW, Berry DA, et al. NCCN Task Force Report: estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry. J Natl Compr Canc Netw 2009;7(suppl 6):S1-21.
2. Carlson RW, Moench SJ, Hammond ME, et al. On behalf of the NCCN HER2 Testing in Breast Cancer Task Force. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw 2006;4(suppl 3):S1-22.
3. American Society of Clinical Oncology (ASCO). Cancer.net & Cancer Types & Breast Cancer & Diagnosis [Web page]. Alexandria, VA: asco; 2008. [Available at: http://www.cancer.net/patient/Cancer+Types/Breast+Cancer?sectionTitle=Diagnosis; cited May 2012]